# Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)

Source: https://onco.cc/trials/nct05374915/  
OnCo record `nct05374915` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of REM-001 photodynamic therapy in advanced solid tumours, run by Kintara Therapeutics, Inc., active and no longer recruiting.

## Summary

Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC) is a phase 2 interventional study registered as NCT05374915 by Kintara Therapeutics, Inc., with 15 participants enrolled, started 2024-02-12 and due to reach its primary completion in 2025-12-30. Interventions recorded: REM-001 photodynamic therapy.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05374915
- Phase: 2
- Setting: An Open-Labeled, Single Arm Phase 2 Efficacy and Safety Study of REM-001 Photodynamic Therapy (PDT) for Treatment of Cutaneous Metastatic Breast Cancer (CMBC) That is Refractory or Not Eligible for Radiotherapy or Surgery
- Sponsor: Kintara Therapeutics, Inc.
- Enrolled: 15

## Sources

- ClinicalTrials.gov NCT05374915: https://clinicaltrials.gov/study/NCT05374915

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct05374915.json